Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing

Le, B.T., Paul, S., Jastrzebska, K., Langer, H., Caruthers, M.H. and Veedu, R.N. (2022) Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing. Proceedings of the National Academy of Sciences, 119 (36). Art. e2207956119.

[img]
Preview
PDF - Published Version
Download (2MB) | Preview
Free to read: https://doi.org/10.1073/pnas.2207956119
*No subscription required

Abstract

Recent advances in drug development have seen numerous successful clinical translations using synthetic antisense oligonucleotides (ASOs). However, major obstacles, such as challenging large-scale production, toxicity, localization of oligonucleotides in specific cellular compartments or tissues, and the high cost of treatment, need to be addressed. Thiomorpholino oligonucleotides (TMOs) are a recently developed novel nucleic acid analog that may potentially address these issues. TMOs are composed of a morpholino nucleoside joined by thiophosphoramidate internucleotide linkages. Unlike phosphorodiamidate morpholino oligomers (PMOs) that are currently used in various splice-switching ASO drugs, TMOs can be synthesized using solid-phase oligonucleotide synthesis methodologies. In this study, we synthesized various TMOs and evaluated their efficacy to induce exon skipping in a Duchenne muscular dystrophy (DMD) in vitro model using H2K mdx mouse myotubes. Our experiments demonstrated that TMOs can efficiently internalize and induce excellent exon 23 skipping potency compared with a conventional PMO control and other widely used nucleotide analogs, such as 2′-O-methyl and 2′-O-methoxyethyl ASOs. Notably, TMOs performed well at low concentrations (5–20 nM). Therefore, the dosages can be minimized, which may improve the drug safety profile. Based on the present study, we propose that TMOs represent a new, promising class of nucleic acid analogs for future oligonucleotide therapeutic development.

Item Type: Journal Article
Murdoch Affiliation(s): Centre for Molecular Medicine and Innovative Therapeutics
Publisher: National Academy of Sciences
Copyright: © 2022 The Authors.
URI: http://researchrepository.murdoch.edu.au/id/eprint/66022
Item Control Page Item Control Page

Downloads

Downloads per month over past year